The CRH1 Antagonist GSK561679 Increases Human Fear But Not Anxiety as Assessed by Startle (original) (raw)

• Baas JM, Grillon C, Bocker KB, Brack AA, CA III Morgan, Kenemans JL et al (2002). Benzodiazepines have no effect on fear-potentiated startle in humans. Psychopharmacology (Berl) 161: 233–247.
  Article CAS Google Scholar
• Bailey J, Papadopoulos A, Diaper A, Phillips S, Schmidt M, van der Ark P et al (2011). Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety. J Psychopharmacol 25: 1199–1206.
  Article CAS PubMed Google Scholar
• Baker DG, West SA, Nicholson WE, Ekhator NN, Kasckow JW, Hill KK et al (1999). Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry 156: 585–588.
  CAS PubMed Google Scholar
• Bijlsma EY, van Leeuwen MLF, Westphal KGC, Olivier B, Groenink L (2011). Local repeated corticotropin-releasing factor infusion exacerbates anxiety- and fear-related behavior: differential involvement of the basolateral amygdala and medial prefrontal cortex. Neuroscience 173: 82–92.
  Article CAS PubMed Google Scholar
• Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T (2008). A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 165: 617–620.
  Article PubMed Google Scholar
• Bond A, Lader M (1974). The use of analogue scales in rating subjective feelings. Brit J Med Psychol 47: 211–218.
  Article Google Scholar
• Buwalda B (1997). Physiological and behavioral effects of chronic intracerebroventricular infusion of corticotropin-releasing factor in the rat. Psychoneuroendocrinology 22: 297–309.
  Article CAS PubMed Google Scholar
• Campeau S, Falls WA, Cullinan WE, Helmreich DL, Davis M, Watson SJ (1997). Elicitation and reduction of fear: behavioural and neuroendocrine indices and brain induction of the immediate-early gene c-fos. Neuroscience 78: 1087–1104.
  Article CAS PubMed Google Scholar
• Coric V, Howard HF, Dan AO, Anantha S, Joseph P, Randy CD et al (2010). Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety 27: 417–425.
  Article CAS PubMed Google Scholar
• Davis M, Walker DL, Lee Y (1997). Roles of the amygdala and bed nucleus of the stria terminalis in fear and anxiety measured with the acoustic startle reflex. Possible relevance to PTSD. Ann NY Acad Sci 821: 305–331.
  Article CAS PubMed Google Scholar
• Davis M, Walker DL, Miles L, Grillon C (2010). Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety. Neuropsychopharmacology 35: 105–135.
  Article PubMed Google Scholar
• Dunlop B, Rothbaum B, Binder E, Duncan E, Harvey P, Jovanovic T et al (2014). Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. Trials 15: 240.
  Article PubMed PubMed Central Google Scholar
• Fabio RD, St-Denis Y, Sabbatini FM, Andreotti D, Arban R, Bernasconi G et al (2008). Synthesis and pharmacological characterization of novel drug like corticotropin-releasing factor 1 antagonists. J Med Chem 51: 7370–7379.
  Article PubMed Google Scholar
• First MB, Spitzer RL, Gibbon M, Williams JBW (2002) Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition. (SCID-I/NP). Biometrics Research, New York State Psychiatric Institute: New York.
  Google Scholar
• Greenblatt DJ, Wright CE (1993). Clinical pharmacokinetics of alprazolam. Clin Pharmacokinet 24: 453–471.
  Article CAS PubMed Google Scholar
• Griebel G, Holsboer F (2012). Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat Rev Drug Discov 11: 462–478.
  Article CAS PubMed Google Scholar
• Grillon C (2008). Models and mechanisms of anxiety: evidence from startle studies. Psychopharmacology 199: 421–437.
  Article CAS PubMed Google Scholar
• Grillon C, Ameli R (1998a). Effects of threat of shock, shock electrode placement, and darkness on startle. Int J Psychophysiol 28: 223–231.
  Article CAS PubMed Google Scholar
• Grillon C, Baas JMP, Pine DS, Lissek S, Lawley M, Ellis V et al (2006). The benzodiazepine alprazolam dissociates contextual fear from cued fear in humans as assessed by fear-potentiated startle. Biol Psychiatry 60: 760–766.
  Article CAS PubMed Google Scholar
• Grillon C, Baas JP, Lissek S, Smith K, Milstein J (2004). Anxious responses to predictable and unpredictable aversive events. Behav Neurosci 118: 916–924.
  Article PubMed Google Scholar
• Grillon C, Chavis C, Covington MS, Pine DS (2009a). Two-week treatment with citalopram reduces contextual anxiety but not cued fear. Neuropsychopharmacol 34: 964–971.
  Article CAS Google Scholar
• Grillon C, Heller R, Hirschhorn E, Kling MA, Pine DS, Schulkin J et al (2011). Acute hydrocortisone treatment increases anxiety but not fear in healthy volunteers: a fear-potentiated startle study. Biol Psychiatry 69: 549–555.
  Article CAS PubMed PubMed Central Google Scholar
• Grillon C, Krimsky M, Charney DR, Vytal K, Ernst M, Cornwell B (2013). Oxytocin increases anxiety to unpredictable threat. Mol Psychiatry 18: 958–960.
  Article CAS PubMed Google Scholar
• Grillon C, Levenson J, Pine DS (2007). A single dose of the selective serotonin reuptake inhibitor citalopram exacerbates anxiety in humans: a fear-potentiated startle study. Neuropsychopharmacology 32: 225–231.
  Article CAS PubMed Google Scholar
• Grillon C, Lissek S, Rabin S, McDowell D, Dvir S, Pine DS (2008). Increased anxiety during anticipation of unpredictable but not predictable aversive stimuli as a psychophysiologic marker of panic disorder. Am J Psychiatry 165: 898–904.
  Article PubMed PubMed Central Google Scholar
• Grillon C, Morgan CA, Davis M, Southwick SM (1998b). Effects of experimental context and explicit threat cues on acoustic startle in Vietnam veterans with posttraumatic stress disorder. Biol Psychiatry 44: 1027–1036.
  Article CAS PubMed Google Scholar
• Grillon C, Pine DS, Lissek S, Rabin S, Bonne O, Vythilingam M (2009b). Increased anxiety during anticipation of unpredictable aversive stimuli in posttraumatic stress disorder but not in generalized anxiety disorder. Biol Psychiatry 66: 47–53.
  Article PubMed PubMed Central Google Scholar
• Harmer CJ, Rogers RD, Tunbridge E, Cowen PJ, Goodwin GM (2003). Tryptophan depletion decreases the recognition of fear in female volunteers. Psychopharmacology 167: 411–417.
  Article CAS PubMed Google Scholar
• Haufler D, Nagy F, Pare D (2013). Neuronal correlates of fear conditioning in the bed nucleus of the stria terminalis. Learn Mem 20: 633–641.
  Article PubMed PubMed Central Google Scholar
• Holsboer F, Ising M (2008). Central CRH system in depression and anxiety—evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 583: 350–357.
  Article CAS PubMed Google Scholar
• Ishitobi Y, Nakayama S, Yamaguchi K, Kanehisa M, Higuma H, Maruyama Y et al (2012). Association of CRHR1 and CRHR2 with major depressive disorder and panic disorder in a Japanese population. Am J Med Genet B 159B: 429–436.
  Article Google Scholar
• Keck ME, Kern N, Erhardt A, Unschuld PG, Ising M, Salyakina D et al (2008). Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. Am J Med Genet B 147B: 1196–1204.
  Article Google Scholar
• Kemp AH, Nathan PJ (2004). Acute augmentation of serotonin suppresses cardiovascular responses to emotional valence. Int J Neuropsychopharmacol 7: 65–70.
  Article CAS PubMed Google Scholar
• Kim S-Y, Adhikari A, Lee SY, Marshel JH, Kim CK, Mallory CS et al (2013). Diverging neural pathways assemble a behavioural state from separable features in anxiety. Nature 496: 219–223.
  Article CAS PubMed PubMed Central Google Scholar
• Klumpers F, van Gerven J, Prinssen E, Niklson I, Roesch F, Riedel W et al (2010). Method development studies for repeatedly measuring anxiolytic drug effects in healthy humans. J Psychopharmacol 24: 657–666.
  Article CAS PubMed Google Scholar
• Koob GF (2008). A role for brain stress systems in addiction. Neuron 59: 11–34.
  Article CAS PubMed PubMed Central Google Scholar
• Koob GF, Zorrilla EP (2012). Update on corticotropin-releasing factor pharmacotherapy for psychiatric disorders: a revisionist view. Neuropsychopharmacology 37: 308–309.
  Article CAS PubMed Google Scholar
• Lee Y, Davis M (1997). Role of the hippocampus, the bed nucleus of the stria terminalis, and the amygdala in the excitatory effect of corticotropin-releasing hormone on the acoustic startle reflex. J Neurosci 17: 6434–6446.
  Article CAS PubMed PubMed Central Google Scholar
• Liang KC, Melia KR, Miserendino MJD, Falls WA, Campeau S, Davis M (1992). Corticotropin-releasing factor: long-lasting facilitation of the acoustic startle reflex. J Neurosci 12: 2303–2312.
  Article CAS PubMed PubMed Central Google Scholar
• Meloni EG, Jackson A, Gerety LP, Cohen BM, Carlezon WA Jr. (2006). Role of the bed nucleus of the btria terminalis (BST) in the expression of conditioned fear. Ann NY Acad Sci 1071: 538–541.
  Article PubMed Google Scholar
• Refojo D, Schweizer M, Kuehne C, Ehrenberg S, Thoeringer C, Vogl AM et al (2011). Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. Science 333: 1903–1907.
  Article CAS PubMed Google Scholar
• Sautter FJ, Bissette G, Wiley J, Manguno-Mire G, Schoenbachler B, Myers L et al (2003). Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects. Biol Psychiatry 54: 1382–1388.
  Article CAS PubMed Google Scholar
• Scaife JJC, Langley RRW, Bradshaw CCM, Szabadi EE (2005). Diazepam suppresses the acquisition but not the expression of ‘fear-potentiation’ of the acoustic startle response in man. J Psychopharmacol 19: 347–356.
  Article CAS PubMed Google Scholar
• Schmitz A, Grillon C (2012). Assessing fear and anxiety in humans using threat of predictable and unpredictable aversive events (the NPU-threat test). Nat Protoc 7: 527–532.
  Article CAS PubMed PubMed Central Google Scholar
• Sink KS, Walker DL, Freeman SM, Flandreau EI, Ressler KJ, Davis M (2013). Effects of continuously enhanced corticotropin releasing factor expression within the bed nucleus of the stria terminalis on conditioned and unconditioned anxiety. Mol Psychiatry 18: 308–319.
  Article CAS PubMed Google Scholar
• Spielberger CD (1983) Manual for the State-Trait Anxiety Inventory. Consulting Psychologist Press: Palo Alto, CA.
  Google Scholar
• Tellew JE, Lanier M, Moorjani M, Lin E, Luo Z, Slee DH et al (2010). Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties. Bioorg Med Chem Lett 20: 7259–7264.
  Article CAS PubMed Google Scholar
• Valdez GR (2006). Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date. CNS Drugs 20: 887–896.
  Article CAS PubMed Google Scholar
• Walker D, Yang Y, Ratti E, Corsi M, Trist D, Davis M (2009a). Differential effects of the CRF-R1 antagonist GSK876008 on fear-potentiated, light- and CRF-enhanced startle suggest preferential involvement in sustained vs phasic threat responses. Neuropsychopharmacology 34: 1533–1542.
  Article CAS PubMed Google Scholar
• Walker DL, Miles L, Davis M, Miles LA (2009b). Selective participation of the bed nucleus of the stria terminalis and CRF in sustained anxiety-like versus phasic fear-like responses. Prog Neuropsychopharmacol Biol Psychiatry 33: 1291–1308.
  Article CAS PubMed PubMed Central Google Scholar
• Zorrilla EP, Logrip ML, Koob GF (2014). Corticotropin releasing factor: a key role in the neurobiology of addiction. Front Neuroendocrinol 35: 234–244.
  Article CAS PubMed PubMed Central Google Scholar